EP1.04-02 Predictors of Lung Toxicity in First Line Pembrolizumb for Advanced NSCLC: An Interim Analysis of PRELUTOX Study

Bonti, V.; Teriaca, M. A.; Lavacchi, D.; Perna, M.; Caini, S.; Mazzoni, F.; Maragna, V.; Rosi, E.; Giannelli, F.; Cozzi, D.; Visani, L.; Calabrò, A.; Bartolucci, M.; Ciccone, L. P.; Mariotti, M.; Flego, N.; Comin, C. E.; Pezzulla, D.; Moroni, C.; Cavigli, E.; Bindi, A.; Caramia, G.; Meacci, F.; Miele, V.; Lavorini, F.; Voltolini, L.; Livi, L.; Scotti, V.; Ferrari, K.

doi:10.1016/j.jtho.2019.08.2118

In literature incidence of ICI-ILD seems to be higher for NSCLC compared with other cancers: this may be related to the underlying lung status (exposure to tobacco, COPD and the thoracic tumor burden). PFTs have been described in several studies for their capacity to predict lung toxicity. In our preliminary data, during Pembrolizumab therapy, if toxicity does not occur, airways obstruction parameters and lung volumes seem to remain constant and related to the respiratory comorbidity (COPD). The same appears for diffusing capacity. Finally we suppose that the thoracic tumor burden could be related to the risk of lung toxicity but the study is still ongoing

EP1.04-02 Predictors of Lung Toxicity in First Line Pembrolizumb for Advanced NSCLC: An Interim Analysis of PRELUTOX Study / Bonti, V.; Teriaca, M.A.; Lavacchi, D.; Perna, M.; Caini, S.; Mazzoni, F.; Maragna, V.; Rosi, E.; Giannelli, F.; Cozzi, D.; Visani, L.; Calabrò, A.; Bartolucci, M.; Ciccone, L.P.; Mariotti, M.; Flego, N.; Comin, C.E.; Pezzulla, D.; Moroni, C.; Cavigli, E.; Bindi, A.; Caramia, G.; Meacci, F.; Miele, V.; Lavorini, F.; Voltolini, L.; Livi, L.; Scotti, V.; Ferrari, K.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - ELETTRONICO. - 14:(2019), pp. S966-S967. [10.1016/j.jtho.2019.08.2118]